Nationa

MSN Laboratories initiates phase-III trial of Molnupiravir

Our Burea Hyderabad | Updated on May 25, 2021

Clinical trials will be performed on more than 2,400 subjects suffering from mild-to-moderate Covid-19

MSN Laboratories Pvt. Ltd. (MSN) is initiating phase III clinical trial of Molnupiravir capsules for the treatment of Covid-19 in India.

MSN received clinical trial approval from the Drug Controller General of India to perform Molnupiravir Capsules’ efficacy and safety study on mild-to-moderate Covid-19 patients last week.

Hyderabad-based MSN will start its clinical trials in more than 40 sites across the country.

Clinical trials will be performed on more than 2,400 subjects suffering from mild-to-moderate Covid-19.

Molnupiravir is an experimental drug having antiviral properties and is currently under clinical stage study for Covid-19 treatment.

MSN R&D team has developed both the API and formulation, is expecting to launch after successful conclusion of clinical study followed by regulatory approval, according to a release.

As part of the Covid treatment range, MSN has already launched Favilow (Favipiravir) in the strengths of 200mg, 400mg & 800mg, Oselow (Oseltamivir) as 75 mg capsules and licensed Baridoz (Baricitinib) with Eli Lilly,

Published on May 25, 2021

Follow us on Telegram, Facebook, Twitter, Instagram, YouTube and Linkedin. You can also download our Android App or IOS App.

medicine (education)
  1. Comments will be moderated by The Hindu Business Line editorial team.
  2. Comments that are abusive, personal, incendiary or irrelevant cannot be published.
  3. Please write complete sentences. Do not type comments in all capital letters, or in all lower case letters, or using abbreviated text. (example: u cannot substitute for you, d is not 'the', n is not 'and').
  4. We may remove hyperlinks within comments.
  5. Please use a genuine email ID and provide your name, to avoid rejection.